V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.58 USD 1.98% Market Closed
Market Cap: 71.8m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

Operating Margin
VistaGen Therapeutics Inc

-5 207.4%
Current
4 477%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 207.4%
=
Operating Profit
-45.6m
/
Revenue
875.7k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
VistaGen Therapeutics Inc
NASDAQ:VTGN
69.8m USD
-5 207%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-22%
Country US
Market Cap 69.8m USD
Operating Margin
-5 207%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 116.2B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 81.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.8B EUR
Operating Margin
-22%
No Stocks Found

VistaGen Therapeutics Inc
Glance View

Market Cap
69.8m USD
Industry
Biotechnology

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

VTGN Intrinsic Value
2.17 USD
Overvaluation 16%
Intrinsic Value
Price
V

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 207.4%
=
Operating Profit
-45.6m
/
Revenue
875.7k
What is the Operating Margin of VistaGen Therapeutics Inc?

Based on VistaGen Therapeutics Inc's most recent financial statements, the company has Operating Margin of -5 207.4%.